Roche to complete acquisition of U.S. biopharma company Poseida

ZURICH (Reuters) - Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.

Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per share, with additional contingent payment of up to $4 per share.

Source: Investing.com